Business
EyePoint, Inc.: The reports we file or furnish with the SEC, including this Annual Report on Form 10-K, also contain trademarks, trade names and service marks of other companies, which are the property of their respective owners.
Revenue decreased 27.5% to $31.4M, while Net income decreased 77.2% to ($232.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $31.4MWatch
- Profitability — Net income ($232.0M)Watch
- Cash generation — Free cash flow ($243.4M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 1 buys; 9 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as EyePoint, Inc. reports it. History and quarterly detail are in the app.
- License And Collaboration Agreement$16.7M
- Product Rights Agreement$15.9M
- Royalty$13.0M
- Royalty Purchase Agreement$12.7M
- YUTIQ Product$1.6M
Leadership changes
From EyePoint, Inc.'s own filings, the day they're filed.
- Reginald Sanders · director · appointmenteff. 2025-01-08
- Anthony P. Adamis · Directors · departureeff. 2024-09-03
- Stuart Duty · director · appointmenteff. 2023-10-16
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about EyePoint, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.